|
ATRN expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.85109999994992E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.45949999996731E-06 |
| Normal-vs-Stage2 |
4.379200E-01 |
| Normal-vs-Stage3 |
1.56126999999451E-05 |
| Normal-vs-Stage4 |
1.58329999999651E-07 |
| Stage1-vs-Stage2 |
6.662400E-03 |
| Stage1-vs-Stage3 |
4.953000E-01 |
| Stage1-vs-Stage4 |
7.238100E-02 |
| Stage2-vs-Stage3 |
1.996350E-03 |
| Stage2-vs-Stage4 |
3.250000E-04 |
| Stage3-vs-Stage4 |
2.308200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.09550000018766E-07 |
| Normal-vs-AfricanAmerican |
2.620400E-02 |
| Normal-vs-Asian |
1.81109999999318E-05 |
| Caucasian-vs-AfricanAmerican |
2.703200E-01 |
| Caucasian-vs-Asian |
6.619400E-01 |
| AfricanAmerican-vs-Asian |
1.602450E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.29570000001667E-06 |
| Normal-vs-Female |
1.67581999999111E-05 |
| Male-vs-Female |
3.519000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.13659999978877E-07 |
| Normal-vs-Age(41-60Yrs) |
5.5609000000012E-05 |
| Normal-vs-Age(61-80Yrs) |
8.441300E-04 |
| Normal-vs-Age(81-100Yrs) |
7.555500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.695200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.999960E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.199400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.347000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.305000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.030200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.813200E-04 |
| Classical-VS-Follicular |
6.624600E-03 |
| Classical-VS-Other |
1.083380E-01 |
| Classical-VS-Normal |
4.29019999970137E-07 |
| Tall-VS-Follicular |
1.89589999999296E-06 |
| Tall-VS-Other |
6.683400E-01 |
| Tall-VS-Normal |
1.29599997400476E-09 |
| Follicular-VS-Other |
4.125700E-02 |
| Follicular-VS-Normal |
9.846400E-02 |
| Other-VS-Normal |
9.217700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.303760E-03 |
| Normal-vs-N1 |
1.70559999457254E-08 |
| N0-vs-N1 |
4.758300E-04 |
|
|
